Current status of isolated limb infusion with mild hyperthermia for melanoma

Thompson, John F.; Kam, P. C. A.

doi:10.1080/02656730701827565

Cited by 15 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports have suggested the use of regional chemoperfusion as neoadjuvant therapy to shrink tumor size and potentially to facilitate surgical resection. 11,13,20-23 Our study did not specifically evaluate the role of ILI as a neoadjuvant therapy, yet 4 patients were rendered disease free at a median follow-up of 8 months, which is a promising result.…”

Section: Commentmentioning

confidence: 96%

Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms

Turaga¹

2011

Arch Surg

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 96%

Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms

Turaga¹

2011

Arch Surg

View full text Add to dashboard Cite

“…These can be prevented by the injection of a muscle relaxant or by lifting the treated area away from the muscle for cutaneous lesions [Gehl, 2008]. There are other techniques currently available for the treatment of skin melanomas such as chemotherapy, chemo-immunotherapy, isolated limb perfusion [Grünhagen et al, 2006], and isolated limb infusion [Thompson and Kam, 2008]. However, they have lower response rates or their side effects are much more problematic, and they are technically complicated for the physicians.…”

Section: Recent Clinical Evaluations Of Ectmentioning

confidence: 98%

Microsecond and nanosecond electric pulses in cancer treatments

Breton¹,

Mir²

2011

Bioelectromagnetics

185

133

View full text Add to dashboard Cite

New local treatments based on electromagnetic fields have been developed as non-surgical and minimally invasive treatments of tumors. In particular, short electric pulses can induce important non-thermal changes in cell physiology, especially the permeabilization of the cell membrane. The aim of this review is to summarize the present data on the electroporation-based techniques: electrochemotherapy (ECT), nanosecond pulsed electric fields (nsPEFs), and irreversible electroporation (IRE). ECT is a safe, easy, and efficient technique for the treatment of solid tumors that uses cell-permeabilizing electrical pulses to enhance the activity of a non-permeant (bleomycin) or low permeant (cisplatin) anticancer drug with a very high intrinsic cytotoxicity. The most interesting feature of ECT is its unique ability to selectively kill tumor cells without harming normal surrounding tissue. ECT is already used widely in the clinics in Europe. nsPEFs could represent a drug free, purely electrical cancer therapy. They allow the inhibition of tumor growth, and interestingly, nsPEF can target intracellular organelles. However, many questions remain on the mechanism of action of these pulses. Finally, IRE is a new ablation procedure using pulses that provoke the permanent permeabilization of the cells resulting in their death. This technique does not result in any thermal effect, which is its main advantage in current physical ablation technologies. For both the nsPEF and the IRE, the preservation of the normal tissue, which is characteristic of ECT, has not yet been shown and their safety and efficacy still have to be investigated thoroughly in vivo and in the clinics.

show abstract

“…[1][2][3] Although results after ILP are satisfactory, the technique involves a complex and invasive surgical procedure with a substantial risk of complications. 4,5 Isolated limb infusion (ILI) has been developed at the Sydney Melanoma Unit as a simplified and minimally invasive alternative to ILP. 6,7 In essence, ILI is a low-flow ILP performed via percutaneous catheters without oxygenation.…”

mentioning

confidence: 99%

Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma

Kroon

Lin

Kam

et al. 2009

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:Isolated limb infusion (ILI) is an effective and minimally invasive treatment option for delivering regional chemotherapy in patients with metastatic melanoma confined to a limb. Recurrent or progressive disease after an ILI, however, presents a challenge for further treatment. The value of repeat ILI in this situation has not been well documented.METHODS:Forty‐eight patients were identified who had been treated with a repeat ILI. In all patients, a cytotoxic combination of melphalan and actinomycin D was used.RESULTS:The median time between the 2 procedures was 11 months. The complete response (CR) rate after repeat ILI was 23%, compared with 31% after the initial ILI (P = .36). The overall response was 83%, compared with 75% after the first procedure (P = .32). The median duration of response was 11 months (10 months for patients with CR; P = .80), and median survival was 38 months. In those patients achieving a CR, the median survival was 68 months (P = .003). Toxicity after repeat ILI was increased, with 20 patients experiencing Wieberdink grade III limb toxicity (considerable erythema and edema with blistering) and 5 patients experiencing grade IV toxicity (threatened or actual compartment syndrome), whereas after the initial ILI these toxicity grades occurred in 14 patients and 1 patient, respectively (P = .03). No patient experienced grade V toxicity (requiring amputation).CONCLUSIONS:Repeat ILI is an attractive treatment option to achieve limb salvage in patients with inoperable recurrent or progressive melanoma after a previous ILI. It can be associated with significant short‐term regional toxicity, but is well tolerated by most patients, with satisfactory response rates. Cancer 2009. © 2009 American Cancer Society.

show abstract

Current status of isolated limb infusion with mild hyperthermia for melanoma

Abstract: ILI with mild hyperthermia is an established alternative to hyperthermic ILP for patients with recurrent limb melanoma. It can also be used for patients with soft tissue sarcomas and a variety of serious, chronic dermatological conditions.

Cited by 15 publications

References 29 publications

Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms

Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms

Microsecond and nanosecond electric pulses in cancer treatments

Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma

Contact Info

Product

Resources

About